Skip to content

Efficacy of tirofiban for acute cerebral infarction presenting beyond the time window for intravenous thrombolytic therapy

Efficacy of tirofiban for acute cerebral infarction presenting beyond the time window for intravenous thrombolytic therapy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075991
Enrollment
Unknown
Registered
2023-09-21
Start date
2023-09-30
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute cerebral infarction

Interventions

experimental group:Treatment with tirofiban after imaging examination
control group:Intensive lipid-lowering therapy

Sponsors

Tianjin TEDA hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
75 Years to 18 Years

Inclusion criteria

Inclusion criteria: (1) The patient meets the diagnostic criteria for acute cerebral infarction in the 2018 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and all patients have confirmed the presence of infarcted lesions through cranial CT and MRI examinations; (2) The time from onset to admission for treatment is 4.5-8.0 hours; (3) NIHSS score = 6 points at onset; (4) The mRS score before this onset was 0.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) presence of intracranial space occupying, intracerebral hemorrhage or Subarachnoid hemorrhage; (2) Emergency whole brain angiography examination showed severe stenosis or occlusion of the cerebral blood supply arteries (internal carotid artery, anterior, middle, posterior cerebral artery, basilar artery, vertebral artery); (3) Confirmed by cranial MRI examination that the infarct site does not match the responsible blood vessel for treatment; (4) Accompanied by severe heart, lung, kidney, and liver dysfunction; (5) Coma; (6) Contrast agent allergy; (7) Has a tendency for severe bleeding; (8) There are other contraindications for cerebral angiography.

Design outcomes

Primary

MeasureTime frame
NIHSS scores;mRS scores;

Secondary

MeasureTime frame
PT APTT TT FIB;

Countries

China

Contacts

Public ContactZaiyu Guo

Tianjin TEDA hospital

1140627652@qq.com+86 153 0210 0230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026